Medical genome accountability doctrine governance

Introduction

Medical Genome Accountability Doctrine Governance refers to an emerging legal framework governing responsibility for the collection, sequencing, interpretation, storage, sharing, clinical use, and commercialization of an individual's genetic information in healthcare. It becomes particularly important with the expansion of genomic medicine, whole-genome sequencing, precision medicine, genetic screening, pharmacogenomics, gene-editing technologies, and artificial-intelligence systems capable of interpreting genetic data.

There is no universally recognized doctrine formally titled “Medical Genome Accountability Doctrine Governance.” Its principles must therefore be derived from constitutional privacy law, medical negligence, informed consent, data protection, intellectual-property law, bioethics, and public-health regulation.

Genetic information creates special accountability concerns because it is not merely information about one individual. A person's genome may reveal information about biological relatives and potentially about future health risks. Consequently, governance must address both individual autonomy and familial or societal implications.

Constitutional protection of genomic information

In India, the constitutional foundation begins with Justice K.S. Puttaswamy (Retd.) v. Union of India, (2017) 10 SCC 1. The Supreme Court recognized privacy as a fundamental right under Article 21 and identified informational privacy and decisional autonomy as important components of that right.

Genomic information fits strongly within this framework. A person's genetic sequence may reveal susceptibility to diseases, hereditary conditions, ancestry-related information, reproductive risks, and other deeply personal characteristics.

Consequently, collection or use of genomic information should ordinarily satisfy principles of legality, legitimate purpose, necessity, proportionality, and appropriate safeguards.

A medical institution should not assume that obtaining a patient's genome for one clinical purpose automatically authorizes unlimited future use.

Informed consent and genomic testing

Genomic testing creates distinctive consent problems. A patient may consent to testing for one disease but unexpectedly receive information concerning other diseases, hereditary conditions, or family members.

Medical providers should therefore explain, where relevant:

• the purpose of genomic testing;
• the nature of the information being collected;
• possible incidental findings;
• potential implications for relatives;
• storage and retention practices;
• research or secondary use;
• data-sharing arrangements; and
• foreseeable privacy and discrimination risks.

The principle of informed medical choice is supported by Suchita Srivastava v. Chandigarh Administration, (2009) 9 SCC 1, where the Supreme Court recognized personal autonomy in reproductive decision-making.

The UK Supreme Court's approach in Montgomery v. Lanarkshire Health Board [2015] UKSC 11 is also relevant because it emphasizes disclosure of material risks and reasonable alternatives from the patient's perspective.

Incidental findings and medical responsibility

One of the most difficult issues in genomic medicine is the treatment of incidental findings. A genetic test may identify a clinically significant variant unrelated to the original reason for testing.

For example, sequencing undertaken for one suspected disorder might reveal a variant associated with another serious condition.

This creates questions concerning the medical professional's duty to:

1. identify potentially significant findings;
2. determine their clinical validity;
3. communicate appropriate findings;
4. avoid communicating scientifically uncertain results as established facts; and
5. provide suitable genetic counseling where necessary.

Failure to recognize a clinically significant genetic finding may potentially result in negligence where a competent medical professional could reasonably have identified and acted upon it.

Conversely, unnecessary disclosure of uncertain genetic information may cause psychological harm or inappropriate medical intervention.

Genetic privacy and family interests

Genomic information presents a unique privacy problem because it has a relational character. One person's genetic information may reveal information about biological relatives.

This creates tension between individual confidentiality and potential medical interests of family members.

For example, a patient's genetic test may reveal a hereditary cancer risk that could also affect siblings or children. Whether and when healthcare professionals may disclose such information without the patient's consent requires careful balancing.

The privacy principles of Puttaswamy provide a strong basis for protecting individual confidentiality, but medical necessity and applicable professional obligations may sometimes justify carefully limited disclosure.

The appropriate approach should ordinarily emphasize:

• informed consent;
• genetic counseling;
• minimum necessary disclosure;
• protection of confidentiality; and
• consideration of serious and preventable risks.

Genomic databases and secondary use

Large genomic databases are increasingly valuable for medical research. However, secondary use creates accountability risks.

A person may provide DNA for diagnosis and later discover that the information has been used for research, commercial development, population studies, or artificial-intelligence training.

Governance should therefore distinguish between primary clinical use and secondary research or commercial use.

Researchers and institutions should establish clear rules concerning:

• purpose limitation;
• consent;
• de-identification;
• re-identification risks;
• data security;
• international transfers;
• retention periods; and
• commercial partnerships.

Genomic data should not automatically become unrestricted institutional property merely because a patient provided a biological sample.

Genetic discrimination

Genomic information may also be used to discriminate against individuals.

Potential areas include employment, insurance, education, lending, and access to healthcare. An employer, for example, might attempt to exclude an applicant based on a predicted genetic susceptibility to illness.

The legal principle in Griggs v. Duke Power Co., 401 U.S. 424 (1971), although not a genetic-discrimination case, illustrates the importance of examining discriminatory consequences arising from apparently neutral decision-making systems.

Medical genome governance should therefore prevent genetic information from becoming an unjustified basis for denying legitimate opportunities or services.

Genome ownership and intellectual property

Another major governance issue concerns ownership of genetic information and biological materials.

The US Supreme Court's decision in Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), established that naturally occurring DNA is not patentable merely because it has been isolated. However, the Court distinguished naturally occurring DNA from genuinely human-created genetic inventions such as certain complementary DNA.

The decision demonstrates an important legal distinction between naturally occurring biological information and human-created technological inventions.

In India, Novartis AG v. Union of India, (2013) 6 SCC 1, although concerning pharmaceutical patentability rather than genomic data, illustrates the judiciary's willingness to scrutinize claims to medical inventions within statutory patent standards.

Genome sequencing and medical negligence

Medical genome accountability also concerns errors in sequencing and interpretation.

A laboratory may produce an inaccurate sequence, incorrectly classify a genetic variant, or fail to identify an important pathogenic mutation. A physician may then make an incorrect diagnosis or treatment decision.

Liability may potentially arise at several levels:

• laboratory error;
• defective sequencing technology;
• inadequate quality control;
• negligent clinical interpretation;
• failure to update an outdated interpretation; or
• failure to communicate clinically important findings.

The principles of medical negligence recognized in Indian Medical Association v. V.P. Shantha, (1995) 6 SCC 651, provide a general framework for accountability in medical services.

Artificial intelligence and genomic interpretation

Artificial intelligence increasingly assists clinicians in interpreting enormous genomic datasets. Although AI can improve diagnostic capabilities, it introduces additional accountability problems.

An algorithm may incorrectly classify a genetic variant because of incomplete training data, population bias, inadequate validation, or an erroneous model.

A hospital should not be able to avoid responsibility simply by stating that an algorithm generated the recommendation.

A sound governance model should require:

• scientific validation;
• clinical verification;
• human oversight;
• documentation of significant algorithmic recommendations;
• monitoring for population bias;
• cybersecurity;
• version control; and
• mechanisms for correcting erroneous interpretations.

The evidentiary reliability principle recognized in Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), provides a useful analogy for evaluating scientifically based genomic technologies.

Gene editing and enhanced accountability

Genome governance becomes even more significant when genetic information is connected with genome modification.

Somatic gene therapies may affect an individual patient, while germline modifications potentially affect future generations. The latter raises substantially greater ethical and legal questions because future individuals cannot provide consent.

The precautionary principle recognized in Vellore Citizens' Welfare Forum v. Union of India, (1996) 5 SCC 647, provides a useful Indian legal analogy for situations involving significant scientific uncertainty and potentially irreversible consequences.

Governance should therefore distinguish between therapeutic interventions with established safety evidence and experimental or enhancement-oriented genetic modification.

Commercialization of genomic information

Genomic databases have significant commercial value for pharmaceutical research, diagnostic development, biotechnology, and personalized medicine.

Commercial use should not eliminate individual privacy interests.

Where institutions monetize genomic information, governance should address transparency concerning:

• who receives the data;
• the purpose of commercial use;
• whether data may be re-identified;
• whether participants receive any contractual benefits;
• whether data may be transferred internationally; and
• whether future uses require additional authorization.

The contractual relationship between patients and genomic providers should therefore be assessed not merely as a commercial transaction but also as a relationship involving fundamental privacy and medical interests.

Security and data breaches

Genomic information cannot simply be treated like an ordinary password that can be changed after compromise. Once genetic information is disclosed, the underlying biological information cannot realistically be replaced.

Consequently, genomic institutions should implement strong cybersecurity controls, including access restrictions, encryption, audit trails, incident-response procedures, secure storage, and appropriate authentication.

A serious genomic breach can affect not only the individual but potentially biological relatives.

Regulatory accountability framework

A comprehensive Medical Genome Accountability Doctrine should operate throughout the genomic lifecycle:

• Collection: establish lawful purpose and meaningful consent.
• Sequencing: maintain technical accuracy and quality control.
• Interpretation: use scientifically validated methodologies.
• Disclosure: communicate clinically material findings appropriately.
• Storage: apply strong privacy and cybersecurity safeguards.
• Research: establish ethical oversight and appropriate consent.
• Commercialization: disclose secondary and commercial uses.
• Correction: provide mechanisms for correcting significant errors.
• Breach response: investigate and mitigate unauthorized disclosure.
• Remedies: provide appropriate compensation and regulatory sanctions where harm occurs.

Important case-law foundations

The principal authorities supporting the emerging framework include:

• Justice K.S. Puttaswamy (Retd.) v. Union of India, (2017) 10 SCC 1 — privacy, informational autonomy, and dignity.
• Suchita Srivastava v. Chandigarh Administration, (2009) 9 SCC 1 — personal autonomy.
• Indian Medical Association v. V.P. Shantha, (1995) 6 SCC 651 — medical-service accountability.
• Novartis AG v. Union of India, (2013) 6 SCC 1 — pharmaceutical patentability.
• Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013) — patentability of naturally occurring genetic material.
• Montgomery v. Lanarkshire Health Board [2015] UKSC 11 — informed medical disclosure.
• Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993) — scientific reliability.
• Vellore Citizens' Welfare Forum v. Union of India, (1996) 5 SCC 647 — precautionary principle.

These decisions do not establish a formally named Medical Genome Accountability Doctrine. Rather, they provide legal principles from which such a governance framework can be developed.

Conclusion

Medical Genome Accountability Doctrine Governance represents an emerging legal framework for ensuring that genomic medicine remains scientifically reliable, ethically responsible, privacy-protective, and legally accountable.

Its central principle is that genomic information should not be treated merely as another medical dataset. It contains deeply personal and potentially familial information, may influence important medical decisions, and can have consequences extending across generations.

Accordingly, genomic governance should require meaningful consent, privacy protection, scientific validation, responsible interpretation, genetic counseling, cybersecurity, limits on secondary use, protection against discrimination, and clear allocation of responsibility among laboratories, physicians, hospitals, researchers, technology providers, and genomic-data platforms.

As precision medicine and AI-driven genomic analysis expand, the strongest legal model will be one that combines patient autonomy with scientific accountability, ensuring that genomic innovation advances healthcare without converting human genetic information into an uncontrolled source of surveillance, discrimination, or commercial exploitation.